Apmonia Therapeutics announces a new licensing agreement with SATT Nord to strengthen its portfolio of innovative peptides for oncology

Share this post

Share on facebook
Share on linkedin
Share on twitter
Share on email

More to explore

Overall News

Welcome to Reims 2019

Apmonia Therapeutics is honored and delighted to have been elected as most promising #startup of the year during “Welcome to Reims” event last week. We

READ MORE »